GlassScriptPhysician profile
Edmond S Lee
NPI 1790843365
$6,174.07
in general payments reported to CMS, 2019-2025
29 companies · $1,555 in 2025
The $1,555 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $590 · 2020: $241 · 2021: $1,241 · 2022: $553 · 2023: $1,047 · 2024: $946 · 2025: $1,555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,037 · Education: $345 · Long Term Medical Supply Or Device Loan: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,036.98 |
| Education | $344.97 |
| Long Term Medical Supply Or Device Loan | $166.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,989.20 | 2019-2025 | |
| Janssen Biotech, INC. | $1,688.14 | 2021-2025 | Darzalex, Imbruvica, Talvey |
| Pfizer INC. | $330.31 | 2019-2025 | |
| Dova Pharmaceuticals | $273.65 | 2019-2021 | |
| Amgen INC. | $265.02 | 2019-2023 | Lumakras |
| Merck Sharp & Dohme LLC | $178.61 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Takeda Pharmaceuticals U.S.A., INC. | $160.16 | 2022-2023 | Iclusig |
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.28 | 2019-2025 | Gilotrif |
| Astrazeneca Pharmaceuticals LP | $137.66 | 2019-2025 | |
| Astellas Pharma US INC | $118.69 | 2019-2025 | Vyloy |
| Gilead Sciences, INC. | $99.57 | 2019-2025 | Trodelvy |
| Sobi, INC | $84.81 | 2022-2023 | |
| Exelixis INC. | $64.14 | 2024-2025 | Cabometyx |
| Abbvie INC. | $62.65 | 2024 | |
| Eisai INC. | $61.67 | 2023-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Puma Biotechnology, INC. | $54.77 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $52.72 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $43.35 | 2019-2024 | |
| Lilly USA, LLC | $40.70 | 2019 | |
| Tesaro, INC. | $39.85 | 2019 | |
| Genentech USA, INC. | $36.68 | 2019-2024 | Tecentriq Hybreza, Tecentriq |
| Beone Medicines USA, INC. | $34.77 | 2025 | Brukinsa |
| Aveo Pharmaceuticals, INC. | $33.24 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $32.47 | 2024 | Libtayo |
| Adc Therapeutics America, INC. | $30.11 | 2025 | |
| Karyopharm Therapeutics INC. | $29.27 | 2025 | Xpovio |
| Kite Pharma, INC. | $26.69 | 2021 | |
| Immunogen, INC. | $26.21 | 2023 | Elahere |
| Coherus Oncology, INC. | $20.68 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edmond Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.